The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Income tax expense | 0 | - |
| License and collaboration revenue | 25,634 | - |
| Research and development expenses-External Research And Development Expenses | 107,879 | - |
| Research and development expenses-Employee Related Expenses | 84,502 | - |
| General and administrative expenses-External General And Administrative Expenses | 18,265 | - |
| General and administrative expenses-Employee Related Expenses | 30,578 | - |
| Facility and information technology related expenses | 44,076 | - |
| Depreciation and amortization | 16,626 | - |
| Stock-based compensation | 73,796 | - |
| Interest and other income | 33,093 | - |
| Other segment items | 7,294 | - |
| Net loss | -112,728 | -211,561 |
| Depreciation and amortization | 5,560 | 11,066 |
| Amortization of investment discount (premiums) | 4,233 | 8,467 |
| In-process research and development charge | 14,507 | - |
| Stock-based compensation expense | 22,747 | 51,049 |
| Change in operating lease right-of-use assets | 2,573 | 5,297 |
| Change in fair value of derivative liabilities | -2,757 | 3,407 |
| Change in fair value of contingent consideration liabilities | -1,000 | 55 |
| Change in fair value of non-controlling equity investments | 4,937 | 2,334 |
| Realized loss (gain) on sale of marketable securities | -399 | - |
| Prepaid expenses and other current assets | -1,625 | -2,827 |
| Accounts payable | -1,589 | 6,435 |
| Accrued expenses and other liabilities | 1,977 | -8,590 |
| Operating lease liabilities | -3,383 | -6,622 |
| Deferred revenue | -5,661 | -15,936 |
| Other long-term liabilities | -93 | -146 |
| Net cash provided by (used in) operating activities | -81,479 | -180,334 |
| Purchases of property and equipment | 5,011 | 6,201 |
| Purchases of marketable securities | 175,643 | 673,111 |
| Maturities of marketable securities | 240,644 | 383,812 |
| Proceeds from sale of marketable securities | 5,743 | - |
| Cash paid for acquisition, net | 78 | - |
| Net cash provided by (used in) investing activities | 65,655 | -295,500 |
| Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs | 0 | 470,513 |
| Proceeds from issuances of stock under espp | 1,263 | 1,501 |
| Repayment of equipment financings | 0 | 0 |
| Proceeds from exercise of stock options | 412 | 2,474 |
| Net cash provided by (used in) financing activities | 1,675 | 474,488 |
| Net change in cash, cash equivalents and restricted cash | -14,149 | -1,346 |
| Cash and cash equivalents at beginning of period | 290,111 | - |
| Cash and cash equivalents at end of period | 274,616 | - |
Beam Therapeutics Inc. (BEAM)
Beam Therapeutics Inc. (BEAM)